Viatris (VTRS) Stock Forecast & Price Target

Viatris is attractive because its core generics business is stabilizing after prior disruptions, with developed markets generics returning to growth and a sizable patent-cliff opportunity of about $175Bn in branded revenue coming off patent between 2025-2030, of which it targets roughly 70%. The company also has a clearer path to revenue and EBITDA growth in 2026 after three consecutive years of declines, helped by new launches, a shift up the complexity curve, and improving performance in Europe, Greater China, and JANZ. Beyond the base business, the pipeline adds meaningful upside through differentiated assets such as selatogrel, cenerimod, and fast-acting meloxicam, while the modernized women’s health patch franchise supports longer-term margin and revenue expansion.

Viatris is viewed negatively because its core US generics business faces ongoing pricing and competitive pressure, and if the shift toward complex generics does not outpace those headwinds, growth could stall and margins may not expand as hoped. Its outlook is also vulnerable to pipeline disappointments, since selatogrel underpins a $1Bn-plus peak sales estimate and cenerimod already failed its Phase 2b CARE primary endpoint, raising the risk that key development assets will not meaningfully offset base-business weakness. In APAC, forecasts depend on regional CAGR targets, but Greater China is exposed to volume-based procurement and JANZ to structural generic price cuts, leaving the company reliant on a fragmented portfolio of legacy products to sustain performance.